Study of Statins and Coronary Artery Disease Progression in Melanoma Patients Receiving Checkpoint Inhibitors

What this Trial Is About

Researchers are conducting a prospective observational study to understand the natural progression of coronary plaque buildup in people with melanoma who are treated with immune checkpoint inhibitors ICIs. The study focuses on assessing coronary atherosclerosis and cardiovascular risk factors in this population. It is sponsored by Monash University and takes place across several sites in Australia. Participants are observed without any experimental treatments being administered by the study. The study evaluates how statin use relates to the amount and progression of coronary artery disease in patients treated with ICIs. The study also looks at the effects of using CT coronary angiography CTCA to guide preventive statin therapy. Various outcomes are assessed over an 18-month period. During the study, participants undergo imaging tests such as CTCA and assessments of their cardiovascular risk factors and quality of life. Researchers will track major cardiovascular events, melanoma progression-free survival, and overall survival. The study requires follow-up visits and imaging, and participants are monitored for up to 18 months to gather these data.

Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS